Clinical Trial Update: Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

The Phase 1/2 trial of cetuximab in combination with carboplatin and paclitaxel for non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• ERBITUX (cetuximab)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 1, Phase 2 | Status: COMPLETED